BIO: Jazz is auditioning new bandmates in an M&A market ripe with talent

“It's a good time to be investing in and acquiring innovation,” Jazz Pharmaceuticals CEO Bruce Cozadd says, as the company scouts for deals at the BIO International Convention. Cozadd is hunting for acquisitions in neurology and oncology, which would back up a portfolio that includes Epidiolex for seizures and Xyrem for narcolepsy. The full neurology portfolio brought in $654 million in the first quarter of the year, according to a recent earnings report. Meanwhile, the oncology programs collected $228.9 million and is fresh off new data for HER2-targeting bispecific antibody zanidatamab, which is partnered with Zymeworks.